Sema4 Holdings Corp. Investors: November 7, 2022 Last Day to actively participate in the case. Please contact the Portnoy Law Firm to recover your losses
07 nov. 2022 14h36 HE
|
Portnoy Law
LOS ANGELES, Nov. 07, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sema4 Holdings Corp. (“Sema4” or the “Company”) (NASDAQ: SMFR, SMFRW) investors that a class action has been filed on...
Sema4 Holdings Corp. Investors: Please contact the Portnoy Law Firm to recover your losses; Last days to actively participate in the case; November 7, 2022
20 oct. 2022 08h00 HE
|
Portnoy Law
LOS ANGELES, Oct. 20, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sema4 Holdings Corp. (“Sema4” or the “Company”) (NASDAQ: SMFR, SMFRW) investors that a class action has been filed on...
Sema4 Holdings Corp. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm
15 sept. 2022 13h16 HE
|
Portnoy Law
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Sept. 15, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Sema4 Holdings Corp. (“Sema4”...
Sema4 Holdings Corp. Equity Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Sema4 Holdings Corp. (SMFR)
12 sept. 2022 14h23 HE
|
Robbins LLP
SAN DIEGO, Sept. 12, 2022 (GLOBE NEWSWIRE) -- The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that...
Sema4 to Participate at Two Investor Conferences in June 2022
26 mai 2022 08h00 HE
|
Sema4
STAMFORD, Conn., May 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will participate...
Sema4 Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 mai 2022 16h05 HE
|
Sema4
STAMFORD, Conn., May 04, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that, effective as of May 2, 2022, the...
Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of its Diagnostic and Clinical Data Platforms
02 mai 2022 07h45 HE
|
Sema4
Acquisition creates an AI-driven advanced health intelligence company, now leveraging one of the largest genomic testing platforms in the U.S. Katherine Stueland, former President and CEO of GeneDx,...
Sema4 to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
26 avr. 2022 16h05 HE
|
Sema4
STAMFORD, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for...
Sema4 Achieves HITRUST CSF Certification
06 avr. 2022 08h00 HE
|
Sema4
STAMFORD, Conn., April 06, 2022 (GLOBE NEWSWIRE) -- Sema4 (NASDAQ: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that its health intelligence platform,...
Sema4 and Mount Sinai Use Integrative Network Analysis to Identify Potential New Lung Cancer Therapy
05 avr. 2022 08h00 HE
|
Sema4
STAMFORD, Conn., April 05, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an artificial intelligence (AI)-driven genomic and clinical data intelligence platform company, and researchers from the...